Pharma major Glenmark says the operating environment is challenging given the slowdown in India and longer time taken by the US drug regulator for product approvals. It is expecting a 20 percent revenue growth in FY14.
first published: May 8, 2013 11:14 am
A collection of the most-viewed Moneycontrol videos.
Live: Nifty fails to defend 25,100, breaks 4-day surge | Closing Bell
Live: Can bulls continue to defend Nifty's 25,100 zone? | Opening Bell
Live: Nifty holds gain for 4th day, above 25,100 on weekly expiry day | Closing bell
Zoho CEO Mani Vembu On Why India Needs Arattai, Growth Surge And Integrating Businesses | Exclusive
